NCT04635943View on ClinicalTrials.gov

Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

August 29, 2020

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
Covid19Coronavirus InfectionSARS-CoV Infection
Interventions
DRUG

Ivermectin

One daily dose of NOXAL-Ivermectin Oral Solution (6 mg/mL) at 300mcg/kg for three (3) consecutive days. A weight-equivalence table will be used to determine each participant´s dose (number of oral drops/day).

DRUG

Placebo

The placebo presentation will be an oral drop solution undistinguishable from ivermectin, but without this device pharmaceutical ingredient.

Trial Locations (1)

15103

Hospital Nacional Cayetano Heredia, Lima

All Listed Sponsors
collaborator

Barcelona Institute for Global Health

OTHER

lead

Universidad Peruana Cayetano Heredia

OTHER

NCT04635943 - Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19 | Biotech Hunter | Biotech Hunter